Tralokinumab

ADBRY

Open Tralokinumab in the interactive console ↗

Pronunciation: tral-oe-KIN-yoo-mab (AD-bree)

Tralokinumab ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Tralokinumab ballicule

Tralokinumab ADBRY mascot mnemonic cartoon — Visual mnemonic: Tralokinumab mascot
**“Cadbury, Try lookin’ (maybe)”**

What it isIL-13 monoclonal antibody; moderate-to-severe atopic dermatitis.

Why this oneUnlike dupilumab, it isolates IL-13 rather than blocking both IL-4 and IL-13 signaling.

What limits itConjunctivitis and injection-site reactions are the main tolerability problems.

Tralokinumab molecular structure (skeletal formula) — Molecular structure: Tralokinumab

FDA-approved for

Moderate-to-severe atopic dermatitis (2021)

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Moderate-to-severe atopic dermatitis	Adults	Loading 600 mg SC (four 150 mg or two 300 mg), then 300 mg every other week	May consider 300 mg q4w after 16 wk if clear/almost clear and <100 kg	—
Moderate-to-severe atopic dermatitis	Pediatric 12–17 y	Loading 300 mg SC (two 150 mg), then 150 mg every other week	150 mg every other week	—

Renal Undefined

Hepatic Undefined

Instructions

SC injection into thigh or abdomen (upper arm if given by caregiver)
Complete age-appropriate vaccinations before starting
May be used with or without topical corticosteroids
Allow to reach room temperature before injecting; do not inject into damaged/bruised skin
Autoinjector for adults only; prefilled syringe for ≥12 y

Available strengths

inj 150 mg/mL

Cautions

Hypersensitivity, including anaphylaxis and angioedema
Conjunctivitis and keratitis
Treat pre-existing helminth infections before starting
Avoid live vaccines during treatment

Adverse reactions

Upper respiratory tract infections
Conjunctivitis
Injection site reactions
Eosinophilia

Pregnancy Limited human data; monoclonal antibody actively transported across placenta; no adverse effects in animals

Lactation No data; maternal IgG present in breast milk

Cost

Tralokinumab (ADBRY)

Strength		#/mo	generic $/unit	CostPlus
150 mg/mL	inj	per unit		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Tralokinumab is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Principal riskConjunctivitis, though less than with dupilumab

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilityConjunctivitis, keratitis and hypersensitivity

Open Tralokinumab in the interactive console ↗